Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease.
Innocenti T, Roselli J, Lynch EN, Apolito P, Parisio L, Bagnoli S, Macrì G, Rogai F, Tarocchi M, Milani S, Galli A, Milla M, Dragoni G.
Innocenti T, et al. Among authors: tarocchi m.
Eur J Gastroenterol Hepatol. 2021 Dec 1;33(1S Suppl 1):e574-e579. doi: 10.1097/MEG.0000000000002166.
Eur J Gastroenterol Hepatol. 2021.
PMID: 35048649